FTC Opens a Deeper Look at Covetrus-MWI, and Vet Distribution's Math Gets Worse

The Federal Trade Commission has begun issuing civil investigative demands to customers and other market participants as part of its review of the proposed $3.5 billion merger between Covetrus and MWI Animal Health, according to regulatory-intelligence outlet MLex. The move signals a substantive antitrust inquiry into a deal that would cut the number of major national veterinary distributors from three to two, a structural shift every clinic and hospital group buying vaccines, pharmaceuticals, and diagnostics through that channel should be tracking.

FTC issues information demands in the Covetrus-MWI merger review

MLex reported on July 28 that the FTC has sent civil investigative demands, or CIDs, to third parties connected to the deal, seeking information on veterinary product distribution, market conditions, and barriers to entry. A CID is a formal fact-finding tool the agency uses when a merger review moves beyond the standard waiting period into deeper scrutiny of competitive effects.

The underlying deal was announced in February. Covetrus and MWI Animal Health, a unit of pharmaceutical distributor Cencora, agreed to combine in a transaction valued at $3.5 billion. Under the terms, Cencora receives $1.25 billion in cash, $800 million in preferred equity, and $1.45 billion in common equity, while retaining a 34.3% non-controlling stake in the combined company. Covetrus CEO Ben Wolin framed the deal at announcement as a way to "offer more solutions to more customers" and "create savings" across the animal health supply chain.

The companies built regulatory uncertainty into their own planning. The merger agreement makes closing contingent on "customary closing conditions, including receipt of required regulatory approvals," and Cencora's fiscal 2026 guidance, which runs through September 30, does not assume the deal closes before then.

Why three national vet distributors becoming two squeezes clinics

Companion-animal practices in the US source vaccines, pharmaceuticals, diagnostics, and supplies through a small number of national-scale distributors, with Covetrus, MWI Animal Health, and Patterson Veterinary generally cited as the three with the reach to serve clinics at scale. Combining two of the three would leave practices with fewer options for negotiating price, terms, and service levels, particularly for independent clinics and smaller regional groups that lack the purchasing leverage of a large consolidator.

Antitrust attorney Joel Thayer, quoted in coverage of the FTC's information requests, argued the deal reads less like a shift from three players to two and more like a shift toward a duopoly given the combined entity's scale, putting its share of veterinary distribution volume at roughly 75%. That figure is Thayer's own public estimate rather than a number drawn from an FTC filing or company disclosure, and it has not been independently corroborated elsewhere. Thayer's framing invokes the concentration threshold from the 1963 Supreme Court case United States v. Philadelphia National Bank, which treated roughly 30% combined market share as a rough trigger for antitrust concern. A 75% figure, if accurate, would sit far past that line.

For operators, the stakes run in two directions. Veterinary practice owners, including the PE-backed roll-ups active elsewhere in this newsletter's coverage, depend on distribution competition to keep input costs and service reliability in check; margin assumptions built into practice-acquisition models generally treat supplier terms as a known, stable variable. Fewer national distributors also means less redundancy if one partner has a stockout, a pricing dispute, or a service disruption. On the other side, manufacturers of pharmaceuticals and diagnostics that sell through these channels could see commercial terms simplify with fewer major distribution partners to negotiate with, though likely at the cost of pricing leverage over time.

The review also sits one layer up the supply chain from the clinic-level consolidation this newsletter has tracked all year, including the Bond Vet and Small Door merger and the sale-leaseback deal between FCPT and Mission Pet Health. Those deals changed who owns and operates veterinary practices. A Covetrus-MWI combination would change who supplies nearly all of them, regardless of ownership structure.

Whether the FTC escalates to a Second Request

The clearest signal of how seriously the FTC is treating this deal is whether the agency escalates from CIDs to a formal Second Request under the Hart-Scott-Rodino Act, which would extend the review timeline further and typically precedes either a negotiated settlement, a lawsuit to block the deal, or clearance with conditions. Reporting on the FTC's information requests has also referenced the possibility of the agency seeking to block the merger in federal court under Section 5 of the FTC Act if it concludes the deal would substantially lessen competition.

Watch for an independent, sourced market-share figure, ideally from an FTC complaint, consent order, or company disclosure, since the 75% estimate currently circulating traces to a single attorney's public comment rather than a regulatory filing. Also watch for the first public comment from Covetrus or Cencora addressing the CIDs directly, and for whether Patterson Veterinary, the remaining major independent national distributor, weighs in given how directly its competitive position is affected. An FTC block or forced divestiture would likely chill future distribution-level M&A across animal health; clearance would signal the agency's tolerance for concentration in this specific, less-visible layer of the pet care supply chain.

Related Analysis

• Central Pet Distribution spins out as a Phillips-led JV, moving pet specialty into consolidation
• A human-medical distribution giant just crossed into the vet channel

Source: Covetrus-MWI Animal Health deal draws US FTC information requests to third parties, via MLex; Trump FTC Investigates Veterinary Consolidation Amid Soaring Petflation Costs, via The Daily Caller; Covetrus and MWI Animal Health to Merge, via BusinessWire